vTv Therapeutics ( (VTVT) ) has issued an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
OnKure Therapeutics plans to terminate its License Agreement with vTv Therapeutics LLC, ending the development of the ppar-δ agonist program. This move, effective January 2025, might impact investors interested in the pharmaceutical collaborations and the future of vTv’s intellectual property ventures.
Learn more about VTVT stock on TipRanks’ Stock Analysis page.
